Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Q2 2024 Earnings Presentation

41 slides from Day One Biopharmaceuticals's earnings presentation, Jul 30, 2024

  1. Slide 1: Day One Biopharmaceuticals Targeted Therapies for People of All Ages

    Day One Biopharmaceuticals Targeted Therapies for People of All Ages July 2024

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Cancer Therapies for People of All Ages

    Cancer Therapies for People of All Ages Develop medicines for genomically-defined cancers Establish first-in-class position through rapid registration pathways Expand to adolescent and adult populations in parallel and pursue those opportunities with the same commitment we do for children Our Approa

  4. Slide 4: Our Pipeline

    1 OJEMDA has received accelerated approval by the U.S. Food and Drug Administration. 2 FIREFLY-1 is an open-label, pivotal Phase 2 trial. 3Ex-U.S. license agreement with Ipsen to commercialize OJEMDA (tovorafenib) outside the U.S. DAY301 is a license agreement with MabCare Therapeutics for exclusive

  5. Slide 5: OJEMDA (tovorafenib) Relapsed or Refractory BRAF-altered pLGG

    OJEMDATM (tovorafenib) Relapsed or Refractory BRAF-altered pLGG

  6. Slide 6: OJEMDA Now Approved In The U.S.

    OJEMDA Now Approved In The U.S. OJEMDA is the first and only FDA Approved therapy for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation *This indication is approved under accelera

  7. Slide 7: Pediatric Low-Grade Glioma: The Most Common Type Of Brain Tumor In Children

    Pediatric Low-Grade Glioma: The Most Common Type Of Brain Tumor In Children pLGGs are chronic and relentless, with patients suffering profound tumor and treatment-associated morbidity that can impact their life trajectory over the long term1 A Serious and Life-Threatening Disease For the majority of

  8. Slide 8: Sources

    Source: 1. Heitzer AM, Raghubar K, Ris MD, et al. Neuropsychological functioning following surgery for pediatric low-grade glioma: a prospective longitudinal study. J Neurosurg Pediatr. 2019;1-9. doi:10.3171/2019.9.PEDS19357. 2. Bryant R. Managing side effects of childhood cancer treatment. J Pediat

  9. Slide 9: U.S. Prescribing Information For OJEMDA

    Overview U.S. Prescribing Information For OJEMDATM (tovorafenib) *This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial. INDICATION

  10. Slide 10: Efficacy Summary From OJEMDA Prescribing Information

    Efficacy Summary From OJEMDATM (tovorafenib) Prescribing Information Overall response rate (RAPNO-LGG) in 76 evaluable patients 51% Response (IRC) RAPNO-LGG n n (%) 95% CI ORR, n (%) BRAF fusion or rearrangement BRAF V600 mutation Prior MAPKi use MAPKi-naïve Median DOR, months Median TTR, months Ran

  11. Slide 11: Safety Summary From OJEMDA Prescribing Information

    Warnings and Precautions Hemorrhage Skin toxicity, including photosensitivity Hepatotoxicity Effect on growth Embryo-fetal toxicity Use in NF1- associated tumors Safety Summary From OJEMDATM (tovorafenib) Prescribing Information No boxed warnings or contraindications TEAEs Preferred Term, n (%) Any

  12. Slide 12: Estimated BRAF-Altered pLGG Patient Population In The U.S.

    Estimated BRAF-Altered pLGG Patient Population In The U.S. ~26,000 ~2,000-3,000 ~1,100 Recurrent/Progressive Total Addressable Patient Population per Year6 at Steady State* Incidence of Treatment-Eligible Frontline Patients4,5 Prevalence of Systemically-Treated Patients Under 251-5 Up to 75% of pLGG

  13. Slide 13: What Physicians & Caregivers Are Looking For In A Therapy

    What Physicians & Caregivers Are Looking For In A Therapy Effective in stopping or shrinking tumors Manageable safety profile Minimal disruption to child’s life What HCP’s are Seeking “The goal is not interfering with the child’s life.” – Ped Onc, Chicago Ad Board “Our time with our kids is precious

  14. Slide 14: Product Profile Aligns With What Physicians Are Looking For

    Product Profile Aligns With What Physicians Are Looking For In A Therapy Data from Pivotal Phase 2 FIREFLY-1 trial. Meaningful tumor stabilization or shrinkage may be possible with OJEMDA. In the clinical trial: 51% of children experienced tumor shrinkage by at least 25% 82% of children saw their tu

  15. Slide 15: Robust Q2 Performance Driven by Successful Execution & Strong Patient Demand

    Robust Q2 Performance Driven by Successful Execution & Strong Patient Demand All 200 target accounts reached in first 2 weeks post-approval Accelerated Customer Engagement Over 150 patients on OJEMDA Quick transition of EAP patients Strong new patient starts ramp, demonstrating underlying demand Rap

  16. Slide 16: Coverage Approval Rates are High Across Commercial and Medicaid Payers

    Coverage Approval Rates are High Across both Commercial and Medicaid Payers Despite Limited Published Coverage Reported Coverage1 Percent of Covered Lives 1Metrics Based on 265.4M Commercial & Medicaid Lives. Artia Solutions - Medicaid Coverage Status Report and Breakaway Partners LLC – Breakaway Pa

  17. Slide 17: Patient Support Program Supporting Access

    Patient Support Program Supporting Access DEDICATED PATIENT NAVIGATOR COPAY CARD PROGRAM PHONE & VIDEO CONSULTATIONS COVERAGE DELAY PROGRAM PATIENT ASSISTANCE PROGRAM COVERAGE INTERRUPTION SUPPORT

  18. Slide 18: Well-Positioned For Commercial Execution And Sustained Growth

    Well-Positioned For Commercial Execution And Sustained Growth Continuing Launch Trajectory Increase breadth & depth of Prescribers Establish OJEMDA in the 2nd line Solidify payer coverage policies

  19. Slide 19: FIREFLY-2 / LOGGIC Pivotal Phase Trial of Tovorafenib in Frontline pLGG

    FIREFLY-2 / LOGGIC Pivotal Phase 3 Trial of Tovorafenib in Frontline pLGG

  20. Slide 20: FIREFLY-2/LOGGIC Pivotal Phase Trial Of Tovorafenib In Frontline pLGG

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial Of Tovorafenib In Frontline pLGG Trial Design * COG or SIOPe-LGG regimen. Abbreviations: CHG, chiasmatic, hypothalamic glioma; DoR, duration of response; LGG, low-grade glioma; ORR, objective response rate; QoL, quality of life; QW, once weekly; SoC, standard o

  21. Slide 21: DAY301 PTK7 Targeted Antibody Drug Conjugate (ADC)

    DAY301 PTK7 Targeted Antibody Drug Conjugate (ADC)

  22. Slide 22: DAY301: Next Generation ADC Targeting PTK7

    DAY301: Next Generation ADC Targeting PTK7 1 Cho BC, et al. Ann Oncol. (34; Suppl 2): S460-S461, 2023. PTK7: Clinically-Validated ADC Target DAY301: Potential First-in-Class Asset Substantial Development and Commercial Opportunities for DAY301 Anti-tumor activity of anti-PTK7 ADC demonstrated in Pha

  23. Slide 23: PTK7: A Clinically-Validated ADC Target

    PTK7: A Clinically-Validated ADC Target 1 Phase 1b study of PF-06647020/ABBV-647. MMAE; Monomethyl Auristain E. Potential opportunity for a next-generation PTK7 ADC with improved therapeutic index Clinical results for cofetuzumab pelidotin1 demonstrated proof of concept for PTK7-targeted ADCs Cofetu

  24. Slide 24: DAY301: Potential First-In-Class Asset

    DAY301: Potential First-In-Class Asset 1) Damelin M, et al. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions. Sci Transl Med. 2017. HNSTD, Highest Non-Severely Toxic Dose; P-gp, P-glycoprotein. DAY301 has been designed to maximize therape

  25. Slide 25: DAY301: First-in-Class Potential

    DAY301: First-in-Class Potential PDX 362310 TNBC H-score 255 PDX 362797 SCLC H-score 210 PDX LD1-200615 HNSCC H-score 120 0 1,000 2,000 3,000 0 20 40 60 80 Tumor Volume (mm3) (Mean ± SEM) Days Post Administration 0 1,000 2,000 3,000 4,000 0 7 14 21 28 Tumor Volume (mm3) (Mean ± SEM) Days Post Admini

  26. Slide 26: DAY301: Encouraging Development And Commercial Opportunities

    DAY301: Encouraging Development And Commercial Opportunities Indication PTK7 Expression (>1+) U.S. Patient Population Cases/deaths ORR at Relapse Median OS at Relapse Endometrial 100%2 67,880/13,2503 39%7 9 months7 Esophageal SCC​ 76%1 22,370/16,1303 5%4 3 months4 Gastric 35%2 26,890/10,8803 12%14 6

  27. Slide 27: DAY301-001: Initial Phase 1/2a Clinical Trial Design

    DAY301-001: Initial Phase 1/2a Clinical Trial Design DL, Dose Level; RD, Recommended Dose; BOIN, Bayesian Optimal Interval; HNSCC, Head and Neck Squamous Cell Carcinoma; SCLC, Small Cell Lung Cancer; SCC, Squamous-Cell Carcinoma; NSCLC, Non-Small Cell Lung Cancer Phase 1a: Monotherapy Dose Escalatio

  28. Slide 28: Summary

    Summary

  29. Slide 29: Second Quarter 2024 Financial Results

    Second Quarter 2024 Financial Results All financial information is unaudited. 1 Includes stock-based compensation expense of $4.7 million and $9.4 million for the three and six months ended 6/30/24, and $3.4 million and $6.8 million for the three and six months ended 6/30/23, respectively. 2 Include

  30. Slide 30: Priorities as a Commercial-Stage Company

    Priorities as a Commercial-Stage Company Expand awareness amongst physicians and establish broad coverage to enable patient access Establish OJEMDA as the standard of care for relapsed or refractory pLGG harboring a BRAF alteration Provide a positive and supportive experience when initiating OJEMDA

  31. Slide 31: Appendix

    Day One x Appendi 31

  32. Slide 32: Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations

    Tovorafenib Inhibits Both BRAF Fusions And BRAF V600 Mutations Tovorafenib is an investigational, oral, selective, CNS-penetrant, type II RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase Activity in tumors driven by both RAF fusions and BRAF V600E mutations Tablet and

  33. Slide 33: Pivotal Phase 2 Trial Of Monotherapy Tovorafenib In Relapsed Or Progressive pLGG (FIREFLY-1)

    June 5, 2023 data cutoff. 1 Wen PY, et al. J Clin Oncol. 2010;28(11):1963-1972. 2 Fangusaro J, et al. Lancet Oncol. 2020;21(6):e305–316. 3 van den Bent MJ, et al. Lancet Oncol. 2011;12(6):583-593. Abbreviations: CBR, clinical benefit rate; IRC, independent review committee; C, cycle; D, day; LGG, lo

  34. Slide 34: Data from Pivotal Phase FIREFLY-1 Trial

    Data from Pivotal Phase 2 FIREFLY-1 Trial June 5, 2023 data cutoff

  35. Slide 35: FIREFLY-1 Baseline Patient Characteristics

    FIREFLY-1 Baseline Patient Characteristics June 5, 2023 data cutoff. *Includes 6 patients with BRAF duplication and 2 with BRAF rearrangement per fluorescence in situ hybridization or in situ hybridization. †Includes tumors that were extending into multiple regions of the brain, leptomeningeal disea

  36. Slide 36: Tumor Response To Tovorafenib Using RAPNO-LGG, RANO-LGG and RANO-HGG

    Tumor Response To Tovorafenib Using RAPNO-LGG, RANO-LGG and RANO-HGG Maximum change in tumor size (%) Maximum change in tumor size (%) Maximum change in tumor size (%) RAPNO-LGG RANO-LGG RANO-HGG June 5, 2023 data cutoff. BOR, best overall response; CBR, clinical benefit rate; CI, confidence interva

  37. Slide 37: Duration Of Tovorafenib Therapy For All Patients With RAPNO-LGG Evaluable Lesions

    Duration Of Tovorafenib Therapy For All Patients With RAPNO-LGG Evaluable Lesions June 5, 2023 data cutoff. Patients Overall treatment duration (months) 5.3 Months 13.8 Months Median time to response Median duration of treatment

  38. Slide 38: Duration Of Tovorafenib Therapy For All Patients With RANO-HGG Evaluable Lesions

    Duration Of Tovorafenib Therapy For All Patients With RANO-HGG Evaluable Lesions Patients Overall treatment duration (months) June 5, 2023 data cutoff. 3.0 Months 16.6 Months Median time to response Median duration of treatment

  39. Slide 39: Duration Of Tovorafenib Therapy For All Patients With RANO-LGG Evaluable Lesions

    Duration Of Tovorafenib Therapy For All Patients With RANO-LGG Evaluable Lesions Patients Overall treatment duration (months) June 5, 2023 data cutoff. 5.5 Months 14.4 Months Median time to response Median duration of treatment

  40. Slide 40: Tumor Response To Tovorafenib Across Three Assessment Criteria

    Tumor Response To Tovorafenib Across Three Assessment Criteria Were Consistent Across BRAF Fusion And Mutation Patients, and Patients With Prior MAPK Treatment June 5, 2023 data cutoff. 1 Fangusaro J, et al. Lancet Oncol. 2020;21(6):e305–316. 2 Fangusaro J, et al. Lancet Oncol. 2020;21(6):e305–316.

  41. Slide 41: Tovorafenib Safety Data (n=137)

    Tovorafenib Safety Data (n=137) June 5, 2023 data cutoff. Treatment-emergent AEs ≥25% any grade in arms 1 & 2. AE, adverse event; ALT, Alanine transaminase; AST, aspartate aminotransferase; COVID-19, Coronavirus disease 2019; CPK, creatine phosphokinase; LDH, lactate dehydrogenase; RTI, respiratory

Day One Biopharmaceuticals — Q2 2024 Earnings Presentation on 6ix